The observed OS difference may therefore be attributed to the more pronounced tumour response, reflected by the depth-of-response data, in combination with the more favourable treatment sequence of anti-EGFR treatment followed by anti-VEGF than the other way round.16 Here, VEGFA is linked to neoplasm.